Skip to content

Immutep Ltd. Sustainability Reports

Immutep Limited is a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases. The company is a pioneer in therapeutics related to the Lymphocyte Activation Gene-3 (LAG-3) protein.

Sector: Professional & technical services

Country: Australia

Exchange: Australian Securities Exchange

ISIN: AU000000IMM6

13 reports from 2011 to 2025